Screening and Impact of Neuropathic Pain in Young Individuals With Sickle Cell Disease.

IF 2.4 3区 医学 Q2 HEMATOLOGY Pediatric Blood & Cancer Pub Date : 2024-12-17 DOI:10.1002/pbc.31493
Amira Adly, Maha Mohammed, Ahmed Aboata, Ghada Wassif, Marwa Nassef, Sara Makkeyah
{"title":"Screening and Impact of Neuropathic Pain in Young Individuals With Sickle Cell Disease.","authors":"Amira Adly, Maha Mohammed, Ahmed Aboata, Ghada Wassif, Marwa Nassef, Sara Makkeyah","doi":"10.1002/pbc.31493","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To assess the frequency of neuropathic pain (NP) and its impact in young patients with sickle cell disease (SCD).</p><p><strong>Methods: </strong>We used the ID-Pain (ID-P) questionnaire and a bedside clinical sensory testing (CST) as screening tools for NP and performed sensory nerve conduction study (SNCS) for all the participants. The impact of pain was assessed using Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaires and Pediatric Quality of Life Inventory (PedsQL) SCD module.</p><p><strong>Results: </strong>The mean age was 12.4 years. The ID-P questionnaire revealed that 20.5% of patients likely had NP, while 10 (34%) of the participants had abnormal CST, and only two patients (4.5%) had abnormal SNCS. On the PROMIS pain scores, the mean pain intensity score was 7.9 ± 2.0. Pain interference was the most affected domain in both patients and parent proxy reports (mean ± SD T-score 63.4 ± 6.6 and 65.2 ± 6.6, respectively) which was worse than other domains including pain quality-sensory and affective, and pain behavior (median T-scores of 47.8, 63.0, and 56.2, respectively). The mean global health-related quality of life (HRQoL) score of the children was 50.3 ± 12.1 indicating poor quality of life.</p><p><strong>Conclusion: </strong>We report the utility of simple tools like ID-P questionnaire and CST for screening of NP in young individuals with SCD.</p>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31493"},"PeriodicalIF":2.4000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pbc.31493","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To assess the frequency of neuropathic pain (NP) and its impact in young patients with sickle cell disease (SCD).

Methods: We used the ID-Pain (ID-P) questionnaire and a bedside clinical sensory testing (CST) as screening tools for NP and performed sensory nerve conduction study (SNCS) for all the participants. The impact of pain was assessed using Patient-Reported Outcomes Measurement Information System (PROMIS) questionnaires and Pediatric Quality of Life Inventory (PedsQL) SCD module.

Results: The mean age was 12.4 years. The ID-P questionnaire revealed that 20.5% of patients likely had NP, while 10 (34%) of the participants had abnormal CST, and only two patients (4.5%) had abnormal SNCS. On the PROMIS pain scores, the mean pain intensity score was 7.9 ± 2.0. Pain interference was the most affected domain in both patients and parent proxy reports (mean ± SD T-score 63.4 ± 6.6 and 65.2 ± 6.6, respectively) which was worse than other domains including pain quality-sensory and affective, and pain behavior (median T-scores of 47.8, 63.0, and 56.2, respectively). The mean global health-related quality of life (HRQoL) score of the children was 50.3 ± 12.1 indicating poor quality of life.

Conclusion: We report the utility of simple tools like ID-P questionnaire and CST for screening of NP in young individuals with SCD.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
镰状细胞病年轻患者神经性疼痛的筛查及其影响
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pediatric Blood & Cancer
Pediatric Blood & Cancer 医学-小儿科
CiteScore
4.90
自引率
9.40%
发文量
546
审稿时长
1.5 months
期刊介绍: Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.
期刊最新文献
Childhood pancreatic neuroendocrine neoplasms: A national experience. Disparities in Global Authorship and Data Source in the Pediatric Blood and Cancer Journal 2011-2021: Realities and Strategies for Improvement. Comment on: Access to Legacy-Oriented Interventions at End of Life for Pediatric Oncology Patients: A Decedent Cohort Review. Effective Use of ALK Inhibitors in EML4::ALK-Positive Lymphatic Malformations. Health-Related Quality of Life Among Discharged Patients With Hemophagocytic Lymphohistiocytosis: A Follow-Up Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1